Endocrine Abstracts

The growth of prostate cancer (PCa) can be suppressed by androgen deprivation therapy (ADT). However, in a significant proportion of men receiving ADT PCa progresses to castration-resistant prostate cancer, associated with activation of intratumoral androgen biosynthesis and induced androgen receptor (AR) expression. Accordingly, we have recently shown that the castration-resistant VCaP (CR-VCaP) xenografts express high level of AR and retain detectable intratumoral androgen c...

Background: Prostate cancer is a major global challenge due to the increasing number of aging population and frequency of diagnosis. During the past decade new treatments have been targeted to the androgen signaling axis either by inhibiting the binding of androgens to androgen receptor (AR) and AR nuclear translocation, or by inhibiting androgen production via CYP17A1 enzyme. Despite the significant progress on the research and new therapies, CRPC is still incurable and there...